Megan Hollasch

Articles

When Does the PD-1 Inhibitor Come Before the Hedgehog Inhibitor for Neoadjuvant Basal Cell Carcinoma?

April 11th 2024

Experts discuss when to use the PD-1 inhibitor cemiplimab vs the hedgehog inhibitor vismodegib as neoadjuvant treatment in non-melanoma skin cancers.

The New Frontier With Integrative Oncology: Shooting for the Stars

April 11th 2024

Richard T. Lee, MD, and Edward S. Kim, MD, MBA, discuss the benefits of integrative oncology and exploring integrative approaches at the Cherng Family Center for Integrative Oncology at City of Hope.

PSMA-Directed Targeted Alpha Therapy Shows Activity in Heavily Pretreated Metastatic CRPC

April 10th 2024

FPI-2265 showed promising activity in patients with metastatic castration-resistant prostate cancer which was similar to prior safety and efficacy data reported.

Dual Checkpoint Inhibition Leads to Higher Response Rates vs Anti–PD-1 Therapy in High-Risk Resectable Melanoma

April 9th 2024

Ipilimumab plus nivolumab increased response rates vs anti–PD-1 monotherapy, but also increased grade 3 or 4 immune-related adverse effects, in melanoma.

Olaparib With Chemotherapy Does Not Elicit Improved Outcomes vs Chemotherapy Alone in BRCA Wild-Type TNBC

April 8th 2024

Olaparib on a gap schedule with chemotherapy does not improve responses vs chemotherapy alone in the neoadjuvant setting for patients with BRCA wild-type TNBC.

Cadonilimab Plus Oxaliplatin and Capecitabine Offers Survival Benefit in Gastric/GEJ Cancer

April 7th 2024

Cadonilimab plus oxaliplatin and capecitabine leads to survival benefit in gastric/GEJ adenocarcinoma, regardless of PD-L1 expression.

Koo Looks to the Future With PSMA PET Imaging in Prostate Cancer

April 4th 2024

Phillip J. Koo, MD, highlights future directions regarding PSMA PET imaging and key takeaways from a presentation he gave on the precision imaging tool.

Metastasis-Directed Radiotherapy Represents Significant Advancement in Prostate Cancer

April 4th 2024

Daniel Spratt, MD, discusses how evolving radiation therapy techniques in prostate cancer can reduce adverse effects and shorten treatment courses.

Recommendations Further Aid in Elucidating the Role of PSMA PET Imaging in Prostate Cancer

April 3rd 2024

Phillip J. Koo, MD, discusses how PSMA PET will be used in clinical trials, the RADAR VI guidelines for using the precision imaging tool, and more.

Segmenting the Utility of ADCs in NSCLC: How These Agents Are Affecting Second-Line Standards

April 3rd 2024

Keeping investigators on the edge of their seats, new data from clinical trials evaluating ADCs continue to impress.

A Medical Oncologist’s Insights on Cannabis Use in the Care of Patients With Hematologic Malignancies

April 2nd 2024

Lindsay Wilde, MD, explains when cannabis may be appropriate and how she’s seen the agent affect quality of life for her patients.

Evidence-Based Integrative Oncology Approaches Forge a New Path in Cancer Care

April 1st 2024

Richard T. Lee, MD, discusses integrative oncology approaches and the development of the Cherng Family Center for Integrative Oncology at City of Hope.

Unpacking the Role of Cannabis in Oncology as Reclassification of the Drug Pends

March 29th 2024

Brooke Worster, MD, MS, FACP, and chief medical officer at EO Care, details what oncologists should know about medical cannabis pending the expectant marijuana reclassification from a Schedule I to a Schedule III drug.

All Eyes Are on IL-15 in Early Phase Studies

March 29th 2024

A deep dive into IL-15 targeted agents including N-803, those in the pipeline, and the fusion protein SAR445877 which Martin E. Gutierrez, MD, sheds light on.

The Breast Cancer Index Impacts Physicians’ Decision to Extend Endocrine Therapy for HR+ Early-Stage Disease

March 28th 2024

Incorporating the Breast Cancer Index test assay into practice affected clinicians’ decision to offer endocrine therapy in HR+ early-stage disease.

EZH2 Expression and TP53 Mutation Results in Inferior Outcomes in MCL

March 21st 2024

TP53 mutation and EZH2 expression negatively affect outcomes in mantle cell lymphoma, with a synergistic negative effect.

ctDNA Offers Potential Biomarker for PARP Inhibitor Maintenance Therapy in Epithelial Ovarian Cancer

March 20th 2024

ctDNA may aid clinicians in determining whether to proceed with or discontinue PARP inhibitor maintenance therapy for patients with recurrent epithelial ovarian cancer.

SBRT Shines in Early-Stage NSCLC and Demonstrates Efficacy With Immunotherapy

March 16th 2024

Stereotactic ablative radiotherapy has shown clinical benefit in combination with immunotherapy in early-stage NSCLC, making it a viable treatment to consider.

Quad Shot Radiation Plus Immunotherapy Improves Local Control in Advanced Head and Neck Cancer

March 16th 2024

Quad Shot radiation plus a checkpoint inhibitor significantly improved local control vs Quad Shot alone and was well tolerated as a palliative treatment for patients with advanced head and neck cancer.

Post-Hoc Analysis Shows Dose-Escalated Radiation is Safe and Efficacious in Intrahepatic Cholangiocarcinoma

March 15th 2024

A post-hoc analysis showed dose escalation of radiation therapy was safe and elicited similar efficacy in intrahepatic cholangiocarcinoma.